400 related articles for article (PubMed ID: 28505977)
21. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485
[TBL] [Abstract][Full Text] [Related]
22. Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.
Bangen KJ; Clark AL; Werhane M; Edmonds EC; Nation DA; Evangelista N; Libon DJ; Bondi MW; Delano-Wood L;
J Alzheimers Dis; 2016 Mar; 52(3):849-61. PubMed ID: 27031472
[TBL] [Abstract][Full Text] [Related]
23. Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.
Li W; Li R; Yan S; Zhao Z; Shan Y; Qi Z; Lu J;
Eur J Neurol; 2023 Mar; 30(3):587-596. PubMed ID: 36448771
[TBL] [Abstract][Full Text] [Related]
24. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
Landau SM; Horng A; Fero A; Jagust WJ;
Neurology; 2016 Apr; 86(15):1377-1385. PubMed ID: 26968515
[TBL] [Abstract][Full Text] [Related]
25. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
[TBL] [Abstract][Full Text] [Related]
26. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
[TBL] [Abstract][Full Text] [Related]
27. Suspected non-AD pathology in mild cognitive impairment.
Wisse LEM; Butala N; Das SR; Davatzikos C; Dickerson BC; Vaishnavi SN; Yushkevich PA; Wolk DA;
Neurobiol Aging; 2015 Dec; 36(12):3152-3162. PubMed ID: 26422359
[TBL] [Abstract][Full Text] [Related]
28. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
[TBL] [Abstract][Full Text] [Related]
29. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.
Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA
J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635
[TBL] [Abstract][Full Text] [Related]
30. Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease.
Kljajevic V; Grothe MJ; Ewers M; Teipel S;
Neurobiol Aging; 2014 Sep; 35(9):1973-81. PubMed ID: 24811241
[TBL] [Abstract][Full Text] [Related]
31. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
[TBL] [Abstract][Full Text] [Related]
33. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
34. Hippocampal subregional volume changes in elders classified using positron emission tomography-based Alzheimer's biomarkers of β-amyloid deposition and neurodegeneration.
Busatto Filho G; Duran FLS; Squarzoni P; Coutinho AMN; Rosa PGP; Torralbo L; Pachi CGDF; da Costa NA; Porto FHG; Carvalho CL; Brucki SMD; Nitrini R; Forlenza OV; Leite CDC; Buchpiguel CA; de Paula Faria D
J Neurosci Res; 2021 Feb; 99(2):481-501. PubMed ID: 33073383
[TBL] [Abstract][Full Text] [Related]
35. Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?
Teipel S; Grothe MJ;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):526-36. PubMed ID: 26555082
[TBL] [Abstract][Full Text] [Related]
36. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
37. White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β.
Freeze WM; Jacobs HI; Gronenschild EH; Jansen JF; Burgmans S; Aalten P; Clerx L; Vos SJ; van Buchem MA; Barkhof F; van der Flier WM; Verbeek MM; Rikkert MO; Backes WH; Verhey FR;
J Alzheimers Dis; 2017; 55(1):333-342. PubMed ID: 27662299
[TBL] [Abstract][Full Text] [Related]
38. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
Ota K; Oishi N; Ito K; Fukuyama H; ;
J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
[TBL] [Abstract][Full Text] [Related]
40. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.
Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE
JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
